Status: Recruiting
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors. Primary outcome measure is Processing Speed Index (PSI) 2 years after start of study treatment.
Participants needed: 84
Trial details
Phase: Phase 2Age: 5+Biological sex: AllType: InterventionalSponsor: Region StockholmUpdated: Apr 12, 2024Locations: 2
Eligibility criteria
Age >5 years. [+5]
Allergy/hypersensitivity to lithium or any of the excipients [+8]